Amiodarone is a potent heart medication that demands a careful, individualized approach to safety.

Health · Published 3 October 2026 Swipe more like this →

In short: First synthesized in 1961, amiodarone is a powerful antiarrhythmic drug used to manage complex heart rhythm disorders. While it is highly effective for specific conditions, it carries significant risks, including potential lung and thyroid toxicity. Because it lingers in the body, treatment requires precise, long-term medical supervision.

Amiodarone is a class III antiarrhythmic medication that functions by extending the refractory period of heart cells, effectively slowing the heart's electrical conduction. Since its reintroduction in 1974, it has become a staple for treating life-threatening ventricular arrhythmias and various atrial rhythm disorders. However, its clinical profile is complex; it is not a first-line treatment for cardiac arrest, where evidence of survival benefit remains weak or uncertain. In fact, recent meta-analyses comparing it to lidocaine suggest no clear survival advantage in cardiac arrest scenarios, with some data even favoring lidocaine for in-hospital outcomes.

The drug's safety profile is notoriously challenging. Because amiodarone accumulates in tissues, adverse effects are often dose-dependent and cumulative. Common issues include thyroid dysfunction—affecting 15% to 20% of patients—as well as vision changes, liver abnormalities, and skin photosensitivity. The most severe concern is pulmonary toxicity, such as interstitial lung disease, which can be fatal. Consequently, clinicians must weigh the benefits of rhythm control against these significant risks, often opting for the lowest effective maintenance dose to mitigate toxicity.

Individualization is essential. The drug is contraindicated in patients with specific conduction blocks or severe sinus node dysfunction unless a pacemaker is present. Furthermore, its use in pregnancy is strongly discouraged due to risks to the fetus, though it is sometimes used as an adjunctive therapy for fetal tachyarrhythmia. Given that it takes weeks to reach full effect and can interact with other medications, such as those causing digitalis toxicity, patients require regular monitoring, including blood tests and pulmonary function assessments, to ensure the therapy remains safe over time.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Derived from the Grecian foxglove, this ancient heart medication has a surprisingly narrow safety margin.
• Why this 1978 heart medication remains a cornerstone of modern cardiovascular care
• By 1987 over a quarter of US symphony players had used heart pills against stage fright
• Does chronic medication use undermine the life-saving potential of emergency epinephrine during cardiac arrest?
• Beyond Numbing: How a Common Anesthetic Rewires Biology from Humans to Plants
• Why the blood pressure pill amlodipine can make ankles swell
• The drug that lost its viral edge but found a new life
• Amoxicillin is a staple for children, yet many ear infections don't need it
• Alzheimer’s still has no treatment that reverses it
• Why this common antibiotic works better in your bladder than in your blood
• If a therapy works, it usually stops being alternative
• Amphetamine treats ADHD—and can also hijack reward

More in Health, medicine and disease · More in Health · Latest · A–Z · All topics